Chengdu Origen Biotechnology Co., Ltd.

First Patient Dosed in Phase 1 Trial of KH658 Gene Therapy for Wet AMD

- Chengdu Origen and Vanotech have dosed the first patient in their VAN-2401 Phase 1 trial evaluating KH658, a gene therapy administered via a single suprachoroidal injection for wet AMD. - KH658 utilizes an adeno-associated virus vector encoding a human VEGF receptor fusion protein, designed to deliver continuous anti-VEGF therapy to potentially reduce the need for frequent injections. - The open-label, dose-escalation trial will enroll approximately nine patients with previously treated wet AMD who have responded to anti-VEGF therapy, with primary endpoints focused on safety and tolerability.